Gilead Sciences Inc - GILD STOCK NEWS

Gilead Sciences (GILD) and Genesis Therapeutics have announced a strategic collaboration to discover and develop novel small molecule therapies. The partnership will leverage Genesis' GEMS AI platform to generate and optimize molecules for targets selected by Gilead. Key points include:

- Gilead receives exclusive rights for clinical development and commercialization of collaboration compounds
- Genesis will receive a $35 million upfront payment across three targets
- Additional preclinical, development, regulatory, and commercial milestone payments possible
- Genesis eligible for tiered royalties on net sales
- The deal is expected to reduce Gilead's 2024 EPS by approximately $0.02

This collaboration aims to accelerate drug discovery for challenging targets using generative AI technologies.

Maria Morais, a registered nurse, was diagnosed with primary biliary cholangitis (PBC) in 2018, a rare autoimmune liver disease affecting approximately 130,000 people in the United States. Her journey from diagnosis to liver transplant highlights the challenges faced by PBC patients. Despite initial treatment, Maria's condition progressed rapidly, causing severe symptoms like uncontrollable itching and fluid accumulation in her abdomen. By 2020, she required a liver transplant, receiving 60% of a liver from a friend. Post-transplant, Maria became a patient advocate and peer counselor for others with rare liver diseases. She emphasizes the need for more research and treatment options to address PBC symptoms like itching, fatigue, brain fog, and fluid build-up. Maria's story underscores the importance of awareness and continued efforts to improve the lives of those living with PBC.

Gilead Sciences (Nasdaq: GILD) will present new data on Trodelvy® during the IASLC 2024 World Conference on Lung Cancer from Sept. 7-10, 2024, in San Diego. Key presentations include:

• Initial results from two cohorts of the EVOKE-02 study on Trodelvy in untreated advanced or metastatic non-small cell lung cancer (mNSCLC).
• Subgroup analysis from the EVOKE-01 study showing overall survival improvement in second-line mNSCLC patients non-responsive to prior anti-PD-(L)1 therapy.
• Updated data from the TROPiCS-03 study in extensive stage small cell lung cancer (ES-SCLC).

These findings highlight Trodelvy's potential efficacy for mNSCLC and ES-SCLC, supporting broader investigation and ongoing Phase 3 trials. Trodelvy's safety and efficacy are still under review for these conditions. Trodelvy has a Boxed Warning for severe neutropenia and diarrhea. For more details, please refer to the safety information.

Gilead Sciences, a biopharmaceutical company focused on developing innovative medicines for unmet medical needs, emphasizes the importance of removing barriers to healthcare access. Johanna Mercier, Chief Commercial Officer, highlights Gilead's efforts to improve health equity and increase access to life-changing therapies. These initiatives align with the company's commitment to responsible business practices.

Gilead operates in over 35 countries globally, with its headquarters in Foster City, California. The company's mission is to transform and simplify care for people with life-threatening illnesses worldwide, focusing on areas of unmet medical need.

Gilead Sciences has released a children's book titled 'The Adventure Jar' as part of its ongoing commitment to support families affected by metastatic breast cancer (MBC). The book, created in partnership with the MBC community, illustrates how one family navigates the challenges of a cancer diagnosis while finding joy in their time together. This initiative aims to provide resources and support for people living with MBC, particularly focusing on the impact on children.

Gilead Sciences is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative medicines in areas of unmet medical need. With operations in over 35 countries and headquarters in Foster City, California, Gilead strives to transform and simplify care for people with life-threatening illnesses worldwide.

Gilead Sciences (GILD) has announced its executives' participation in three upcoming investor conferences in September:

• Wells Fargo Healthcare Conference on September 4
• Morgan Stanley Annual Global Healthcare Conference on September 5
• Baird Global Healthcare Conference on September 10

Live webcasts will be available on Gilead's investor page, with replays accessible for at least 30 days. Gilead, a biopharmaceutical company with over three decades of experience, focuses on developing innovative medicines for life-threatening diseases like HIV, viral hepatitis, COVID-19, and cancer. Operating in more than 35 countries, Gilead is headquartered in Foster City, California.

Forbes has recognized Gilead Sciences as one of America's Best Employers For Women for the third consecutive year. This recognition highlights Gilead's commitment to fostering an inclusive workplace where women can make a meaningful impact.

Gilead emphasizes creating a culture that champions women and offers competitive benefits focused on employee wellbeing. The company's approach aligns with its mission to drive innovation and create a healthier world for all people.

This acknowledgment by Forbes underscores Gilead's ongoing efforts to provide an environment where women can thrive professionally and contribute significantly to the company's goals in the biopharmaceutical industry.

Dr. Summer Sitima, Gilead's Commercial Operations Lead in South Africa, shares her personal journey and the company's initiatives to combat HIV in Africa. Growing up during the HIV epidemic, Summer's experiences led her to pursue a career in healthcare. Today, she leads efforts to address the high rate of HIV diagnoses among adolescents in South Africa.

Gilead collaborates with partners to provide HIV testing, treatment, and education. Innovative programs include training barbers and hairdressers as HIV educators, sponsoring charity runs for medical education, and implementing tree-planting initiatives to improve access to healthcare services. These efforts aim to reduce stigma, increase awareness, and improve access to care in resource- African countries where millions live with HIV and hepatitis.

Gilead Sciences has received accelerated FDA approval for Livdelzi (seladelpar) to treat primary biliary cholangitis (PBC) in adults. The approval is based on the Phase 3 RESPONSE study, where 62% of Livdelzi patients achieved the primary endpoint versus 20% on placebo. Livdelzi demonstrated significant reductions in alkaline phosphatase (ALP) levels and pruritus (itching), key markers of PBC progression. As the first and only treatment to show statistically significant improvements in both pruritus and cholestasis markers, Livdelzi challenges the current PBC standard of care. The drug's continued approval may depend on confirmatory trials demonstrating clinical benefits in survival or prevention of liver decompensation.